FGF21 and prostate carcinoma: While clinical development has focused on metabolic diseases such as diabetes and NAFLD, emerging evidence indicates that FGF21 also exerts antitumor effects in cancers including hepatocellular and prostate carcinoma, potentially through modulating autophagy, glycolysis, and ferroptosis (22–26).